
|
Stock Quote (NASDAQ: DNDN)
Price:
14.17
Change:
+ 0.23
Volume:
6,067,700
4:00 PM ET on Feb 3, 2012
Delayed at least 20 minutes.
Provided by eSignal. |
Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.
Feb 1, 2012
Dendreon Announces CEO and Chairman Succession Plan
Jan 31, 2012
Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium
Feb 29, 2012 at 2:00 PM ET
Citi 2012 Global Healthcare Conference
Feb 27, 2012 at 4:30 PM ET
Q4 and Year End 2011 Earnings Conference Call
| MEDCAC 11.17.10 Presentation |
|
397.5 KB |
| Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) |
|
421.1 KB |
Investor Relations |
Media |